MPI Research Continues Toxicology Expansion
News Jul 25, 2007
As part of a series of planned expansions, MPI Research announced the immediate availability of additional toxicology capacity. Through its portfolio of services the company generates critical safety data for the pharmaceutical and biotechnology industries prior to a new drug candidate’s introduction to humans.
Completed July 20th, the 79,000 square foot toxicology expansion project includes the addition of 84 animal rooms, new surgical suites and accommodations for specialized infusion work.
The project is part of a multi-phased expansion plan fueled by the growing research and development needs of the pharmaceutical and biotechnology industries. In 2006, the company completed toxicology expansion projects totaling $65 million, including 95 animal rooms plus significant laboratory and office space.
“Our expansion projects are driven by our customers’ need for timely, cost effective research and development services,” said Bill Parfet, Chairman and Chief Executive Officer of MPI Research. “Our ongoing investments in capacity, service expansions and infrastructure will further assure our customers of timely study starts, quality services, and on-time reporting to keep their drug development programs moving forward.”
A research team developed a microfluidic-based drug screening chip that identifies synergistic interactions between two antibiotics in eight hours. This chip can be a cell-based drug screening platform for exploring critical pharmacological patterns of antibiotic interactions, along with potential applications in screening other cell-type agents and guidance for clinical therapies.READ MORE